-transparent.png){kind=logo}
We compared the effects of epidermal growth factor-urogastrone (EGF-URO) with those of transforming growth factor-alpha (TGF-alpha) on regional blood flow in the anesthetized dog in vivo, and on isolated canine helical coronary artery strips in vitro. Like EGF-URO, TGF-alpha was a potent stimulator of femoral arterial blood flow in vivo; and, when added to the tissue bath in vitro before an agonist, TGF-alpha like EGF-URO was a potent inhibitor of the contractile responses of helical coronary arterial strips to various smooth muscle agonists: norepinephrine (NE), prostaglandin F2 alpha (PGF alpha) and potassium chloride (KCl). Nonetheless, there were marked differences between EGF-URO and TGF-alpha in terms of the two biological responses measured. In terms of blood flow, although the ED50 for the increase in blood flow was similar for EGF-URO and TGF-alpha (ED50 = 0.4 micrograms EGF-URO equivalents per dose), the maximum responsiveness to TGF-alpha (130% increase in flow) was substantially greater than the maximum response to EGF-URO (70% increase in flow). Furthermore, TGF-alpha did not cause tachyphylaxis to subsequent doses of TGF-alpha, whereas a prior dose of either EGF-URO or TGF-alpha desensitized markedly the blood flow preparations to EGF-URO. Different desensitization patterns for the actions of EGF-URO and TGF-alpha also were observed in the arterial strip preparations. The inhibitory action of EGF-URO for agonist (NE, PGF2 alpha or KCl)-mediated contraction was diminished with repeated exposure of the tissue to EGF-URO, whereas the inhibitory action of TGF-alpha persisted with repetitive tissue exposure.(ABSTRACT TRUNCATED AT 250 WORDS)
B S Gan, and
M D Hollenberg, and
K L MacCannell, and
K Lederis, and
M E Winkler, and
R Derynck
August 1985,
Canadian journal of physiology and pharmacology,
B S Gan, and
M D Hollenberg, and
K L MacCannell, and
K Lederis, and
M E Winkler, and
R Derynck
October 1995,
European journal of gastroenterology & hepatology,
B S Gan, and
M D Hollenberg, and
K L MacCannell, and
K Lederis, and
M E Winkler, and
R Derynck
April 1984,
Sheng li ke xue jin zhan [Progress in physiology],
B S Gan, and
M D Hollenberg, and
K L MacCannell, and
K Lederis, and
M E Winkler, and
R Derynck
April 1989,
British medical bulletin,
B S Gan, and
M D Hollenberg, and
K L MacCannell, and
K Lederis, and
M E Winkler, and
R Derynck
December 1991,
Bailliere's clinical endocrinology and metabolism,
B S Gan, and
M D Hollenberg, and
K L MacCannell, and
K Lederis, and
M E Winkler, and
R Derynck
January 1986,
Proceedings of the Western Pharmacology Society,
B S Gan, and
M D Hollenberg, and
K L MacCannell, and
K Lederis, and
M E Winkler, and
R Derynck
November 1990,
The Journal of investigative dermatology,
B S Gan, and
M D Hollenberg, and
K L MacCannell, and
K Lederis, and
M E Winkler, and
R Derynck
January 1989,
The Journal of pharmacology and experimental therapeutics,
B S Gan, and
M D Hollenberg, and
K L MacCannell, and
K Lederis, and
M E Winkler, and
R Derynck
July 2002,
Molecular and cellular biochemistry,
B S Gan, and
M D Hollenberg, and
K L MacCannell, and
K Lederis, and
M E Winkler, and
R Derynck
December 1977,
The Journal of clinical endocrinology and metabolism,
